Hosted on MSN1mon
AbbVie acquires Nimble Therapeutics to boost R&DAbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical ... has announced the completion of its acquisition of Nimble Therapeutics, a move aimed at strengthening its research and development pipeline ...
Hosted on MSN2mon
AbbVie to acquire Nimble Therapeutics for $200mAbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...
Second, with a strong focus on the immunology market, which, as I discussed in the article "Top 4 Immunology Stocks Poised ...
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...
Last month, AbbVie completed its acquisition of Nimble Therapeutics, and it also announced a partnership with Simcere Zaiming and expanded its collaboration with AbCellera. A stock popular with ...
In a separate development, AbbVie has completed the acquisition of Nimble Therapeutics, which is now integrated into AbbVie's operations. The oral peptide interleukin 23 receptor (IL23R ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.
The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
AbbVie (ABBV) and Xilio Therapeutics (XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results